TScan Therapeutics (TCRX) Competitors $2.29 +0.05 (+2.23%) Closing price 04:00 PM EasternExtended Trading$2.34 +0.05 (+2.18%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. MBX, OCGN, ADCT, FULC, INBX, ATXS, CYRX, SLDB, ALMS, and DRUGShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include MBX Biosciences (MBX), Ocugen (OCGN), ADC Therapeutics (ADCT), Fulcrum Therapeutics (FULC), Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Its Competitors MBX Biosciences Ocugen ADC Therapeutics Fulcrum Therapeutics Inhibrx Biosciences Astria Therapeutics CryoPort Solid Biosciences Alumis Bright Minds Biosciences MBX Biosciences (NASDAQ:MBX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment. Does the media refer more to MBX or TCRX? In the previous week, MBX Biosciences had 9 more articles in the media than TScan Therapeutics. MarketBeat recorded 11 mentions for MBX Biosciences and 2 mentions for TScan Therapeutics. MBX Biosciences' average media sentiment score of 1.41 beat TScan Therapeutics' score of 0.32 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is MBX or TCRX more profitable? MBX Biosciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,964.88%. MBX Biosciences' return on equity of -31.33% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A -31.33% -29.96% TScan Therapeutics -1,964.88%-63.33%-40.19% Do analysts prefer MBX or TCRX? MBX Biosciences currently has a consensus price target of $44.00, indicating a potential upside of 172.78%. TScan Therapeutics has a consensus price target of $7.80, indicating a potential upside of 240.61%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75TScan Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals and insiders believe in MBX or TCRX? 82.8% of TScan Therapeutics shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by company insiders. Comparatively, 4.4% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, MBX or TCRX? MBX Biosciences has higher earnings, but lower revenue than TScan Therapeutics. MBX Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/A-$61.92M-$4.54-3.55TScan Therapeutics$6.96M18.67-$127.50M-$1.09-2.10 SummaryMBX Biosciences beats TScan Therapeutics on 9 of the 14 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.12M$3.44B$6.19B$10.60BDividend YieldN/A2.26%5.72%4.86%P/E Ratio-2.1023.2429.6428.46Price / Sales18.67477.59577.46128.87Price / CashN/A44.5736.5560.64Price / Book0.5410.3512.076.53Net Income-$127.50M-$52.53M$3.32B$276.75M7 Day Performance-7.66%-0.22%-0.16%0.20%1 Month Performance27.22%10.89%5.76%1.67%1 Year Performance-55.01%14.19%65.71%32.73% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics2.8269 of 5 stars$2.29+2.2%$7.80+240.6%-57.3%$127.12M$6.96M-2.10100Gap UpMBXMBX Biosciences3.6339 of 5 stars$14.50-2.7%$42.80+195.2%N/A$500.89MN/A-3.19N/AInsider TradeOCGNOcugen1.5417 of 5 stars$1.60-6.4%$6.00+275.0%+62.4%$499.84M$4.05M-8.0080News CoverageADCTADC Therapeutics2.5356 of 5 stars$4.63+4.6%$7.75+67.6%+27.6%$497.25M$70.84M-2.95310Analyst RevisionFULCFulcrum Therapeutics2.7418 of 5 stars$8.75-2.7%$9.60+9.7%+166.7%$486.28M$80M-7.17100News CoverageAnalyst ForecastAnalyst RevisionINBXInhibrx Biosciences1.6756 of 5 stars$34.38+5.9%N/A+99.5%$470.27M$200K-3.25166News CoverageGap UpTrading HaltedATXSAstria Therapeutics1.922 of 5 stars$8.47+1.9%$29.50+248.3%+3.9%$468.97MN/A-4.2130CYRXCryoPort2.9917 of 5 stars$9.40+1.1%$12.56+33.6%+39.3%$465.62M$228.38M7.071,186SLDBSolid Biosciences2.8332 of 5 stars$6.01+0.8%$15.00+149.6%-1.1%$464.10M$8.09M-2.15100ALMSAlumis3.4983 of 5 stars$4.61+3.8%$20.17+337.5%-65.4%$462.05MN/A0.00N/APositive NewsDRUGBright Minds Biosciences3.0991 of 5 stars$64.97+2.7%$81.00+24.7%+31.8%$445.81MN/A-69.86N/APositive News Related Companies and Tools Related Companies MBX Biosciences Competitors Ocugen Competitors ADC Therapeutics Competitors Fulcrum Therapeutics Competitors Inhibrx Biosciences Competitors Astria Therapeutics Competitors CryoPort Competitors Solid Biosciences Competitors Alumis Competitors Bright Minds Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRX Stock Alerts